Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma
NCT06302569Phase 2Recruiting
- Start
- May 2025
- Primary completion
- Oct 2027
- Modality
- Immune Checkpoint Inhibitors, Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, enfortumab vedotin in collecting duct carcinoma (CDC), renal medullary carcinoma (RMC). Started May 2025; status: recruiting.
02
Drugs
pembrolizumabenfortumab vedotin
03
Conditions
collecting duct carcinoma (CDC)renal medullary carcinoma (RMC)
Beyond the preview
Go deeper on NCT06302569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06302569.